A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain
Status: | Completed |
---|---|
Conditions: | Chronic Pain, Dental |
Therapuetic Areas: | Dental / Maxillofacial Surgery, Musculoskeletal |
Healthy: | No |
Age Range: | 18 - 40 |
Updated: | 4/17/2018 |
Start Date: | August 31, 2016 |
End Date: | February 1, 2017 |
A Phase 3, Double-blind, Randomized Safety And Efficacy Study Comparing Multiple Administrations Of Ibu 250 Mg/Apap 500 Mg (Administered As Two Tablets Of Ibu/Apap 125 Mg/250 Mg) To Placebo In The Treatment Of Post Surgical Dental Pain In Adult Subjects
This study is being conducted to determine the overall analgesic efficacy and safety of a
fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation compared to placebo in
subjects who are experiencing post operative pain following surgical extraction of 3 or more
third molar teeth. A review of any reported adverse events will also be completed.
fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation compared to placebo in
subjects who are experiencing post operative pain following surgical extraction of 3 or more
third molar teeth. A review of any reported adverse events will also be completed.
Inclusion Criteria
1. Males and females 18 years to 40 years of age (inclusive).
2. Outpatients who have undergone surgical extraction of 3 or more third molars, of which
at least 2 must be a partial or complete bony mandibular impaction.
3. Subject must have at least moderate pain on the 4 point categorical scale, confirmed
by at least 50 mm on the 100 mm VAS PSR scale within approximately 5 hours (ie, less
than or equal to 5 hours, 15 minutes) after surgery is completed.
4. In general good health and have no contraindications to the study or rescue
medication.
Exclusion Criteria
1. Presence or history of any significant hepatic, renal, endocrine, cardiovascular,
neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic
disorder determined by the Investigator to place the subject at increased risk,
including the presence or history within 2 years of screening of the following medical
conditions/disorders:
- Gastrointestinal ulcer or gastrointestinal bleeding;
- Paralytic ileus or other gastrointestinal obstructive disorders;
- Bleeding disorder.
2. Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID; or to APAP,
tramadol, other opioids, or to their combinations.
3. Prior use of any type of analgesic or NSAID within five half lives of that drug or
less before taking the first dose of investigational product, except for pre
anesthetic medication and anesthesia for the procedure.
We found this trial at
1
site
Click here to add this to my saved trials